CryoPort, Inc.

Robert, if you don't mind, I'm going to add one more. Brandon, I want to just comment on your commercial question here. So as you're aware, we were just talking about it. We focus on a portfolio approach to the clinical and commercial space. And our focus has historically been on growing our clinical trial pipeline and supporting those through commercial launch. That's obviously demonstrating success. And we expect that commercial growth to continue for four primary reasons. One, we're going to see a continued number of approved therapies that expand out on a global basis, which we're seeing evidence of already with additional approvals of folks like Novartis and others. These approved therapies are going to move into earlier lines of treatment. You know, the Gilead Kite product has moved to second line. BMS will be filing for second line, for example, which substantially increases the addressable patient population. And these approved therapies continue to expand indications, right, as well as new therapy launches. So the four of those obviously bode very well from a commercial standpoint for the foreseeable future.

That's just helpful.

And then follow-up on MDE, you mentioned supply constraints. Is that mainly a cost dynamic, or is that also limiting your ability to ship product? And then secondly, you talked about in the packet expanding capacity in the U.S.? Just be more specific about the timeline for that new capacity coming on board.

Yeah, I mean, the capacity expansion is taking place as we speak on an incremental basis. I mean, we've added shifts. We've added people. We've rearranged some of the processes. So, that's incremental, but we also are planning an actual plant expansion and that will take a year or so, but it's in the process.

The last one, Jerry, you got $600 million cash on the balance sheet, not burning that much, unlike a lot of other smaller companies. You put a little bit to work on the share repurchase front, but just curious to get an update on what you see in terms of the acquisition pipeline and where your priorities would be right now. Thanks.

Well, you know, the acquisition pipeline is made up of those areas that we've talked about in the past. And, of course, we're filling in gaps, and we do intend, as I mentioned in my remarks, to be the most compelling, most comprehensive supply chain. chain support system for the life sciences in the world. And so, you know, if you look at our acquisitions, strategic acquisitions take a much longer time, and they're rare. They don't come along every day. Tactical acquisitions, you've seen us make several of those, and you will see us continue to make tactical acquisitions. The one that we made recently, Selling Co., is what I call a tactical acquisition with strategic impact in that it cut out a couple of years of development that we had to go through to qualify ourselves in EMEA because of its licensing and its position and the competency of that staff. It's got a fantastic staff. So we do have a robust acquisition pipeline. We're looking at a lot of opportunities in the space, and we're eager to announce them as they come along. Our cash reserves are very important to us, but we are always mindful that this is shareholder money, and we're prudent in the way we allocate our cash, the way we invest our cash. We don't talk about spending cash. We talk about investing our cash because we're going to return on everything, on every dollar. So it's a great, we have a great outlook. We are in a great position. It's a strong position, but that's about as far as I can go in commenting on how we will be using that capital other than the purchase we, the repurchase we made on the stock.

Very good. Thank you.

The next question is from Preet Sodha with SBB Securities.

Please go ahead.

Hi. You got Michael on for opinion this morning. Congrats Jake for the question. My first one is about a recent proposal, policy proposal from CMS we saw suggesting like a 3% decline to CAR T reimbursement, which continues to be lower than the hospital cost. So overall, we're just wondering if reimbursement updates overall changing your view on uptake for CAR T in the markets?

So I'm going to start, answer a couple of things and then turn it to Dr. Sawicki because he's closer to this. But look, this is a nascent industry. And I think for anyone to be too laser focused on any particular element right now is, you know, it should be taken in context with the fact that it is nascent. It's just beginning. I mean, it's taken a long time for us to get to this point. We still aren't. to use the baseball metaphor, we still aren't out of the first ending. So that doesn't really concern us all that much because there's a different, the paradigm is changing on a consistent basis. So from that, I'm going to let Mark talk about his views and what he's seeing in the marketplace.

No, I think that Jerry's absolutely correct. Just to add to that, the biggest limitation on the space right now isn't reimbursement. It's honestly manufacturing capacity overall. And you can look at this very clearly. A lot of our commercial clients are very candid about obviously the impact and shortage of either drug product manufacturing capacity or viral vector manufacturing capacity. And they're all investing substantially in this space as it relates to bringing new capacity online. You know, from our perspective, that's the biggest impact on scalability is bringing that capacity online. The second is moving these products into earlier lines of treatment. You know, the earlier that they bring them online, and obviously there's a cost justification that they can use, you know, as it relates to the overall spend against a patient demographic component. And a lot of them are using that as an angle that addresses that reimbursement issue. So from our perspective, that's a non-issue. It's really going to be the manufacturing capacity that has the biggest impact on adoption over the next couple of years.

Okay. Thank you, guys. That really helped. And then my other question is about the new bioservice facilities. I was wondering if you had any updates on, like, the revenue ramp-up for these companies. for these facilities? And I know last quarter you said you're thinking 2023 is when they'll actually start meaningfully contributing to revenues. Just wanted to see if there was any update on the outlook.

Again, I'm going to start the answer and then turn it to Dr. Sawicki. So when you think about bioservices, I want you to think about global supply chain centers because that's what these are. This is a It is a revolutionary service, although some folks don't like to look at it exactly that way, but bioservices comes in as a part of the supply chain center. What that means is we'll have world-class logistic services combined with bioservices, which includes biostorage, secondary labeling, It's made to fulfill allogeneic product. Remember, about a third of our trials are allogeneic. So it's married there, and it will provide a lot of services. And that's the core, though. It's built around fulfilling the allogeneic therapies as they come to market. Very few places, in fact, hardly any that we know of are equipped in that way. We're very excited about these. And these supply chain centers, which include bioservices, these first two are in Houston and Morris Plains are just the beginning, of course. And then Cell & Co., that I mentioned, will be adopted to that system. It's already a biostorage operation, and it will be – It will be converted to that system, and that Paris operation that Mark has planned will be a part of that system. But you'll see us opening up more supply chain centers and creating that global supply chain network. And the network is really important. So my guess is that eventually we'll have 18 to 25 global supply chain centers around the world forming that network. And there's a lot of power in having a network because you have redundancy, you have backup, you have more surety, you have less risk by having a network. So I'll let Mark take it from there.

Yeah, the only thing I'll add, and Jerry's absolutely right, the only thing I'll add on it is both of the facilities in the U.S. have their formal grand openings in June. However, there's already robust client activity related to bringing product and activity into both locations. Obviously, the timing and the reason that we were saying that you'll see a more material impact in 2023 is, you know, the validation and onboarding processes of moving, you know, clinical activity or commercial activity into a new space takes some time, and so that time frame is it affords the quality systems and others from these organizations to make those transitions. But the client activity is extremely robust already in both facilities, and we stand by the fact that these will be very, very actively and heavily used as these organizations complete their validation processes.

Okay, thanks for the call there. Yeah, thank you very much. Thank you.

The next question is from David Saxton with Needham. Please go ahead.

Hi, guys. This is Joseph on for David. Just one from us today. You know, appreciate you guys giving guidance. Maybe if you could add some more color on some of the other financial targets you guys have talked about in the past, you know, 55% gross margin, you know, 30% EBITDA margin. 2025, you guys were talking about an ambitious target of $650 to $750 million. I guess where's the timeline for those different targets and what needs to happen? What's going to go into that over the next five or so years for that to happen?

Well, I'll start and then turn it to Robert. The Our target of 650 to 750 remains in place by 2025, but we have no reason to back off of that target, and we continue to think it's achievable. And what goes into that is going to be organic growth and acquisitions, just as we, you know, just the normal thing that we're doing, you know, today. And it's going to be organic growth. It'll be tactical acquisitions. strategic acquisitions, if we're lucky, and partnerships and alliances to move us forward. And, Robert, you may want to comment on margins and other metrics.

Yeah, no, just a few things. And you're absolutely right. You know, the target gross margin is 55%. The adjusted EBITDA is 30%. Again, you have to step back and look at where we are right now. early stages of the cell and gene therapy market. We're the leader in this space, and we're constantly expanding our solutions, and with that, our revenue capture and then market share on a global basis. So with us supporting 690 clinical trials, the maturing of that clinical trial base with now 81 trials in phase three. I mean, this is a significant number. So we believe that, you know, the resulting commercial revenue that we can support will, one, lead to expansion of margins, you know, increase economies of scale, and drive the adjustment of the bottom line. You know, right now we're still in that building phase. You know, there's only a few commercial therapies in the market. So you'll continue to see us build out you know, the global supply chain centers that Jerry was talking about. And in spite of that, we still see a positive adjusted EBITDA for the quarter. We expect that to continue over time. So we do think it's, you know, the aspirational target that we set about a year and a half ago is achievable, and then we're working hard to make that happen. Okay.

Thank you very much. That's all. Thank you.

The next question is from Paul Knight with KeyBank. Please go ahead.

How was the performance of cryogene in the quarter, Rob?

Good. I mean, cryogen, you know, there's a few things to say on cryogen. Cryogen continues to perform well, you know, from a service and solutions perspective. But I think more importantly is really to highlight the expansion plans that are underway. One, you know, the expansion that already happened in terms of the footprint in Houston. And then second, you know, as we talked about, the expansion into other geographies which includes two additional sites in Philadelphia and in Austin. So that will further obviously bring revenue capture. They have a very kind of winning approach to the market in the Houston market, and we'll replicate that in those two additional locations. So you should expect to see as those are put in place, there will be further revenue growth, profitable revenue growth from the cryogen side.

And cryo PDP, how did that perform in the quarter?

All of the business units performed well. Cryo PDP had significant growth year over year and performed very well. You'll continue to see acquisitions that they've made in the past. You'll see more of those as they further expand their geographic footprint in key locations. So, you know, outside of the, you know, kind of one-time impact of the fire damage, you know, that impact the MBE revenue, the revenues were very strong for, you know, Q1.

And last question is, you seem to pay a very attractive price for the Sell & Co. acquisition. What was behind? What was a multiple revenue price lower than what we've seen before?

Well, I think you're right. I mean, we do have a very disciplined approach in terms of, you know, the acquisitions overall. So you look at, you know, the cell and gene acquisition, the cell and co acquisition in particular, I think it was attractive, but it's really more the strategic element that Jared was referring to related in cell and co that really will bring value much more significant value to Cryoport and the Cryoport family of companies. So it's really just, you know, the approach we're taking. We're looking for, you know, strong leadership and entrepreneurial spirit, which, you know, the Cell & Co. management team certainly brings to the table. They have, you know, all of the certifications that would be required. So it allows us to enter into the European market probably two years sooner than we otherwise could have through an organic roadmap, and that's probably a conservative view.

So, Paul, I'd just add a couple of things there. Remember, a big portion of that purchase price is earn out, so number one. And then number two, reinforcing what Robert said about the strategic elements. In addition to meeting all the strategic elements that we wanted and accelerating the us by a couple of years in EMEA, it met all of our financial hurdles, our ROIC and return on investment criteria. It's an excellent acquisition and fantastic people.

The acquisition was $6.7 million and $2.7 million that is earned out on reaching specific milestones. The owner's took some of their purchase price in shares of the company for the further upside that they see in becoming part of CryoCorp.

And then last, would it be fair to assume that the biopharma clinical trial business revenue was up sequentially with your pickup and trial count?

Yeah, short answer. You're talking about the non-commercial, yes. Yeah. Yes, yes, absolutely. Okay, thanks.

The next question is from David Larson with BTIG. Please go ahead.

Hi, congratulations on what looks to me to be like a pretty good quarter. Can you maybe just talk a bit about the impact of inflation that you're seeing on the business specifically freight, can you pass that through to your customers and how quickly can you pass that through? And then also steel and then also any sort of technology components like semiconductors in particular. And then related to inflation, just in terms of the timing of throughput in the labs, are you seeing clinical trial activity sort of just kind of like being extended, which may lead to some sort of, I guess, extended timing to recognize certain pieces of your revenue. Just any color there would be helpful.

David, let me comment in the beginning, and then Robert and Mark may have some additional comments. Look, inflation is my number one worry, because if it's not properly controlled internally, then we get margin squeezes and that sort of thing. So we do have some inflation, and it hits us in all of the areas, just like it does everyone else, because we're not immune to it. I mean, stainless steel, aluminum – semiconductors, all our materials as well as freight. On freight, we pass that through. That's a pass through. On the others, we do pass that through also in terms of price increases. We look at price increases more frequently now than we've ever done ever in the past. We have early warning systems within our company within our companies to let finance know immediately when a price increase is suspicion, not when the order is placed, not when the purchase order is written, not when the invoice comes in, but when they suspicion a price increase. And so that goes to finance. Finance is alerted. and we work vigorously to make sure that we adjust our pricing, you know, to reflect the inflation that's taking place. Now, that pricing sometimes is permanent, if we think it's going to be permanent, and other times it'll be surcharges. And so we work hard to have, like we do on every other situation, we work hard to have control over these situations because they exist, and we face them head-on, and we face them intelligently, and So far, we've been very successful in managing in that way. So, Robert, do you want to comment further on that?

Yeah, no, just to state a few more items and emphasize one that Jerry already mentioned is the transportation piece. That is covered, and that is something that our clients are paying. So that is passed through. But if you look at maybe a different angle, you look at our gross margins, we believe gross margins have stabilized. We actually had a slight uptake sequentially over Q4, about 180. And we expect margins to gradually improve over the coming quarters. As Jerry mentioned, if you look at MBE, they've improved slightly sequentially, but they're still experiencing increased costs in raw materials and inventory. We build up inventory to have safety stock. So some of those costs will take time to pass through to our clients. But we do expect that to continuously improve. And like Jerry said, very, very careful in analyzing any increases that we see in the market for the products and systems that we develop.

And then there was a clinical trial element to your question that Mark can answer, I think, David.

Yeah, I think the only thing I'll add to that is that, you know, we kind of addressed this earlier. You know, we have not seen any slowdown in activity. We have not seen intentional extension of programs, you know, based on market conditions. You know, the trial environment is still extremely robust and very strong. And we haven't seen any impact on obviously the macro events or inflationary considerations that impact any of those things. The market seems to be extremely strong at this point in time from everything that we can see.

Okay, so the activity in like Shanghai and China, that's not having an impact on your business. Is that correct?

Yeah, we don't on a global basis. You can see, I mean, all three geographies continue to grow the total number of trials and trial count. No, we have not seen an impact from a geographic standpoint based on any macro environmental conditions at this point in time.

David, Mark is specifically referring to trials here as he's talking through that. Right, right.

Yeah. So, yeah, the activity is still very strong.

Okay. That's great. Thank you. And then it sounds to me like backlog and demand is still high, pipeline growth is good, and you're adding capacity. I think you have three MVE biologic plants that are actually creating these products. Are you building another plant or are you adding on to one of those plants in order to add more resources?

David, that's certainly in the future that we will look at that. But right now, I'm focused on asset utilization. So when you have a plant that's running one ship, you can run two. When you run two, you can run three. And then if you can go back in and re-engineer the plant, sometimes you can add on to the plants, and we do have that underway at both plants. We're examining adding on to the plants. Then when you do add on, sometimes you can put in automation and other labor-saving processes. So we're looking at all of those things. But the first order of business is not to just go build a new plant. The first order of business is to improve our asset utilization. And we haven't maxed out there yet. So that's our focus.

Okay. And then just one more for me. With the $9 million in, I guess, delayed revenue, I would imagine some of your competition would be looking at that and trying to get in there and take some of that revenue and Just any thoughts on that? What has the competitive response been, if any, and just any color on sort of a competitive environment? I've gotten some questions from some investors around pricing and capabilities and so forth. Just any thoughts that would be helpful?

Oh, yeah, absolutely. It's a really good question that I'm eager to address. MBE has spent 60 years becoming – the preeminent supplier of cryosystems, cryogenic freezers, and doers in the world. It occupies a lauded position for the highest quality, the fairest dealings of any supplier in the world. Our customers have determined that they will ride it through with us. Now, it's caused some pain for some of them because we go through a a robust distribution network globally, but they've stayed with us. Now, I'm sure that the competition has benefited to some degree from the backlogs that we have, but we have those backlogs because of the loyalty of our customers, and those customers are loyal because they know they're going to be dealt with fairly, and they're going to get the highest quality product in their customers. you know, to those services. No one manufactures a product of higher quality than MBE.

Okay. Thanks very much. Appreciate it.

Once again, if you wish to ask a question, please press star, then 1. Our next question is from Juan G. with Burali Securities. Please go ahead.

Thank you for providing the full year guidance here. So maybe, Jerry, can you talk about the rationale to select New Jersey and Houston as your logistics centers? If you can talk about the existing customers and the potential customers that you guys can cover for those two centers, that would be great. And also, for those two centers, will there be any difference in terms of services provided from them?

You know, it's a really good question. And as John Dillinger says, you know, when he was interviewed at one point, he said, you know, why do you rob banks? And he said, that's where the money is. Well, the corollary to that is we're located in these places because in Morris Plains and in Houston because that's where the customers are. We have a huge following in the Houston area. And, of course, the major campuses of all the major, roughly all the major universities players in the pharmaceutical industry are right there around the Morris Plains area. And that's important for us to be in those locations. So it was a no-brainer. And then we already had the CrowdGene facility in Houston, so we can create a campus effect in the Houston area. Morris Plains is very close to the Livingston operation that we have, where we can better serve the customers. As far as the services from these centers, they'll be exactly the same. the SOPs will be the same. This is the network effect I was talking about earlier where we provide redundancy and decrease risk. And we're all about cell viability and about decreasing risk around that cell viability. And we also then want to create, also with that network effect, then we have that redundancy where if there's a catastrophic situation in one place, the other another node can take over and never miss anything. We reduce the risk because clients will be able to store in more than one facility and know it's treated exactly the same, same SOPs and all the facilities making up the supply chain, the global supply chain network. Mark, do you want to comment any further on that?

No, I think you articulated it really well. The only other thing that I would add is As we continue to build out this network, it provides organizations the ability to truncate supply chains and to shorten them to be able to get product into the hands of the patient that much more quickly. And some of these products have a very time-sensitive aspect to them, in particular some of the newer allogeneic portfolio that's coming through where ours may make the difference between a successful or a non-successful outcome. for things that are related to spinal cord or cardio and other aspects. So having a network of facilities that are able to store and distribute these types of product lines will have a substantial beneficial impact for our client base over time.

Got it. Thank you, Jerry and Mark. And another question I have is in the last two quarters, the quarter-over-quarter growth of cell and gene product sales were single digits. And recently, Novartis has mentioned that they have seen lower demand for their product. So I'm just curious, what kind of signals have you guys picked out from your customers? Have you seen maybe the order number in the third quarter and fourth quarter are relatively higher than the second quarter so far?

So I'll start, and then I'll turn it to Mark. Remember, we are the gold standard in terms of – in terms of clinical trials and support of the industry. So it gives us a view that other folks don't have. And, you know, Mark has mentioned that there's a manufacturing capacity constraint. And I've mentioned, too, that this is a nascent industry. It's at the very beginning. And nothing is a straight line in the development of the industry. So there's nothing concerning there to us. But we certainly can see how it could be concerning to others who may not be as involved in the industry and may be looking at it as being more mature than it actually is. But it's still in its very early formative stages, and it's running short of manufacturing capacity. I'll turn it to Mark at this point.

Yeah, Jerry's exactly right. The biggest issue here is manufacturing capacity issues. So if you take a look at Gilead Kite and Bristol Myers, for example, both of those folks have substantial additional manufacturing capacity coming online and have intimated that capacity constraints are restricting their ability to provide product for the addressable patient populations. that they're going after on their product lines. Novartis has seen some loss in product revenue due to competitive factors, which they acknowledge. They've been really focused now on moving to rest of the world because of some of those competitive factors. And they've also obviously been looking at launching this new T-Charge platform, which they believe will substantially reduce manufacturing time. which will reduce costs but also provide a much larger volume of addressable product for patients potentially over time. So everything that you're going to see over the next one to two years in this space from a commercial standpoint is really going to be impacted by this capacity coming online. as well as the move from third line to second line. And then, ideally, some of them are also starting to target moving from second line to first line, which will also have a significant impact on the addressable patient population.

Got it. And one last question from me. In terms of pressure from supply chains, I've seen you guys have a better gross margin in this quarter compared to last quarter. I'm just curious, generally speaking, is it getting better in the first quarter and next quarter versus last year?

We can't say that it is actually getting better. What I can tell you is that we have an incredible sourcing team across all companies, and they do just an incredible job. They foresee, forecast, We provide, you know, put the safety stocks in that Robert referred to earlier. We are in constant contact through our quality organization as well as our procurement organization. We're not, you know, I would say the world is not out of its supply chain issues yet, but I will tell you this. I think that the supply chain will work its way, you know, through all of the issues in the next, you know, a couple of quarters. I think it'll take that long. The biggest issue right now in supply chain is containers, as you know, container availability, but, but that's, that's getting better. Uh, it's not where it needs to be by a long shot. Um, and, and Shanghai Harbor has a lot of, uh, you know, a lot of, uh, of, of the world's containers stuck in, in that Harbor, but it will work through. And, and our folks are on top of things. They're booking things in advance. And, um, You know, like every other problem, we address it forthrightly and work through it. So I guess the bottom line is I think it is getting better, but we're not through it yet.

Got it. That's a very helpful color. Thank you for taking my questions. Yeah.

The next question is from Jacob Johnson with Stevens. Please go ahead.

Hey, good evening. One bigger picture question, and I have a modeling follow-up. I want to talk about these supply chain centers. And as I think about those, I kind of think about the allogeneic opportunity. And obviously, you make two shipments with autologous, and only one with allogeneic. But as we think about the potential volumes from allogeneic therapies and storage kitting packaging, because an allogeneic therapy be a larger revenue opportunity for you all versus some of these autologous ones today?

You know, Jacob, I want Mark to sort of educate you on a couple of things there because I think on the surface, I think you're exactly right in terms of what you might think on the surface about autologous versus, you know, allogeneic. But the fact is allogeneic has to be distributive. And so it's a lot more work, a lot more things going on with allogeneic. And on Togus, there's duplicate doses made. So I won't go any further. I'll just turn it over to Mark because he knows a lot more of the detail and let you take it, Mark.

Yeah, it's a lot more complex than that. So, Jerry's right. The bottom line is that an allogeneic therapy can have as few as one dose, but it could have as many as a dozen doses, depending on the indication and therapy class that's being addressed. So, you may have as few as one shipment. You may have as many as 12, you know, based on the nature of the particular allogeneic therapy. But allogeneic also requires... bulk storage, fulfillment, secondary labeling considerations, which provide, obviously, the supply chain centers have the capacity to support each and every one of those components from a drug product distribution basis. That doesn't mean that Autologous never has those needs, right? And so one of the key elements around having a supply chain infrastructure is for drug product importation and release for a product that's manufactured in country A and dosed in country B. So you have to go through a drug product release process, and that can only occur in a controlled environment. So one of the drivers for buying the Cell & Co., for example, acquisition is the fact that they have QPs on staffing to do drug product release for assets that are being manufactured in the U.S. and released in Europe, and can also support secondary labeling considerations for in-country labeling and language-related considerations. There's a lot of different factors that go into drug product distribution in this space. It's not as simple as autologous is going to be manufactured in a manufacturer setting and then shipped directly to patient. You do have backup doses and you do have other related activities occurring However, Allogeneic does in general have a higher demand need for, you know, a supply chain center based on long-term storage and other fulfillment-related activities in general. So hopefully that helps.

And then just for Robert, just the insurance recoveries around the MBE fire, any thoughts about the timing of when you'll receive those and we'll see those flow through numbers?

You're talking about the, I couldn't understand the first part, insurance?

Yeah, the insurance related to the MB fire, like the business disruption.

Yeah, I mean, that's an ongoing process, and it covers inventory, fixed assets, you know, the business interruption. We have adequate coverage. We've already received, you know, I think around $8 million from the insurance so far. So that's going very well. We're working really hand in glove with the adjuster. Obviously, their interest was to get the plant up and running as quick as we can, and we have the same interest. So that's going to happen over the next quarters. We're probably going to be able to close it off completely by the end of the year, but most of the work should be done within the second quarter, I think.

Okay, thoughtful. Thank you.

This concludes the question and answer session. I'd like to turn the conference back over to Jerry Shelton for closing remarks.

Thank you. And thank you for the conversations we just had. I think there were good questions and all illuminating. In closing, first quarter 2022 is yet another quarter demonstrating our leadership position in temperature control supply chain solutions for the life sciences industry. supporting our markets of biopharma, animal health, and reproductive medicine, and especially lifesaving cell and gene therapies across the clinical and commercial spectrum. Due to our comprehensive brand portfolio, growth initiatives, global reach, and talented employees located in 15 nations who flawlessly execute on our winning strategy daily, we believe 2022 will be another year of results reflecting outstanding growth. We want to thank you for joining us today. We appreciate your continuing support and interest in our company, and we look forward to updating you on our progress again next quarter. We hope you have a good evening.

This concludes today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant evening.